David Hoang
Stock Analyst at Citigroup
(2.20)
# 2,679
Out of 4,734 analysts
28
Total ratings
50%
Success rate
-4.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $17.57 | +30.90% | 4 | Aug 8, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $176 → $160 | $118.00 | +35.59% | 5 | Aug 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $150 → $158 | $143.26 | +10.29% | 4 | Aug 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $26 → $32 | $21.93 | +45.92% | 2 | Aug 2, 2024 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $7 | $1.65 | +324.24% | 1 | Jul 25, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $39.05 | +22.92% | 1 | Jun 21, 2024 | |
| SAGE Sage Therapeutics | Initiates: Sell | $8 | $7.08 | +12.99% | 1 | May 29, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $62 → $60 | $38.52 | +55.76% | 2 | May 10, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $127 → $125 | $91.94 | +35.97% | 3 | May 7, 2024 | |
| SLDB Solid Biosciences | Initiates: Buy | $16 | $3.27 | +389.30% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.07 | +215.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $246.27 | -10.67% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $19.56 | +309.00% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.96 | +211.88% | 1 | Dec 7, 2022 |
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $17.57
Upside: +30.90%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Neutral
Price Target: $176 → $160
Current: $118.00
Upside: +35.59%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $143.26
Upside: +10.29%
Denali Therapeutics
Aug 2, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $21.93
Upside: +45.92%
Acumen Pharmaceuticals
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Harmony Biosciences Holdings
Jun 21, 2024
Initiates: Buy
Price Target: $48
Current: $39.05
Upside: +22.92%
Sage Therapeutics
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $7.08
Upside: +12.99%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Buy
Price Target: $62 → $60
Current: $38.52
Upside: +55.76%
Axsome Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $127 → $125
Current: $91.94
Upside: +35.97%
Solid Biosciences
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $3.27
Upside: +389.30%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $5.07
Upside: +215.58%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $246.27
Upside: -10.67%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $19.56
Upside: +309.00%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.96
Upside: +211.88%